大浪淘沙，沉者为金

带量采购背景下，借鉴日本经验，投资中国创新

2020年7月9日

更多

日本老龄化导致医保控费，行政性降低药价

日本医药短期受到降价冲击，长期超额收益明显

日本从仿制到创新，海外合作推动创新

看好国内研发进入收获期的创新药企

风险提示

收起

医药生物行业2020年度策略：中国医药行业进入创新驱动时期

东吴证券 全铭,焦德智,许汪洋,李颖睿

医药行业深度研究：医保个人账户政策推演：药店龙头争夺统筹机会

中信建投 贺菊颖,刘若飞

医药行业2020年投资策略：行业格局重塑，关注创新药械和CRO

东北证券

刘舒畅,崔洁铭

Page 1/3

Press

Vienna, May 18, 2018

更多

Siemens expands digitalization solutions for the process industries

• Technical prerequisites for Industrie 4.0 fulfilled

• Personalized medicine is driving digitalization of the pharmaceutical industry

• IoT solutions as a growth driver

收起

Content of Premarket Submissions for Management of Cybersecurity in Medical Devices

Guidance for Industry and Food and Drug Administration Staff

Document Issued on: October 2, 2014

更多

The draft of this document was issued on June 14, 2013.

For questions regarding this document contact the Office of Device Evaluation at 301-796-5550 or Office of Communication, Outreach and Development (CBER) at 1-800-835-4709 or 240-402-7800.

U.S. Department of Health and Human Services

Food and Drug Administration

Center for Devices and Radiological Health

Office of Device Evaluation

Office of In Vitro Diagnostics and Radiological Health

Center for Biologics Evaluation and Research

收起

KMU-innovativ: Medizintechnik

Leitfaden für Antragsteller

KMU-innovativ:Medizintechnik

Vorfahrt für anwendungsorientierte Forschung